SCHEMBL23911882

SCHEMBL23911882

CC(C)CC(C)C(=O)NOC1CCCCO1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
EPHX2 P34913 1/20 0.35
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
REN P00797 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
BCHE P06276 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
SLC6A3 Q01959 2/20 0.32
GSTP1 P09211 1/20 0.31
GSTM2 P28161 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19161112 0.83 HPGD (0.37) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL4635116 0.83 MME (0.40) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL7383043 0.83 MMP1 (0.34) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL7411014 0.80 CCNA2 (0.35) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL4635104 0.78 MME (0.41) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL4633172 0.77 MME (0.42) MEN1KMT2ASLC6A3
SCHEMBL4633169 0.77 MME (0.42) MEN1KMT2ASLC6A3
SCHEMBL23735072 0.75 BCHE (0.41) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL7986917 0.75 CCNA2 (0.37) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL1618268 0.75 CCNA2 (0.37) CCNA2CDK2CCNA1CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142535-B2 Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor HANGZHOU INNOGATE PHARMA CO., LTD. (CN) 2021-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11142535-B2 Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor SYK, HDAC1, HDAC2 CCNA2 2794/4885CDK2 351/4885CCNA1 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.